Latest Information Update: 20 Oct 2009
At a glance
- Originator Organon
- Mechanism of Action Testosterone congener stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Andropause; Female genital diseases
Most Recent Events
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 28 Oct 2005 Phase-II clinical trials in Andropause in Netherlands (unspecified route)